NGL Fine Chem Ltd
- Market cap
- ₹ 1,632 Cr.
- P/E
- 28.4x
- P/B
- 4.97x
- 52-week range
- 1,271 – 3,602
- ROE
- 16%
- ROCE
- 17%
- Dividend yield
- 0.1%
- Debt / equity
- 0.37
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →NGL Fine Chem Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)28.4 against a typical 34.3: cheaper than most peers (1st = cheapest).96th of 220
- Sales growth+35.6% against a typical +15.6% from a year earlier.45th of 197
- Profit growth+100% against a typical +18.9% from a year earlier.32nd of 160
- Share price, 3 months−20.1% against a typical −0.5%.180th of 200
- Size₹ 1,632.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).77th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]BBB+ | Stable | 30 Mar 2026 |
| CRISIL | Crisil BBB+ | Stable | 12 Mar 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 30 Mar 2026 | Reaffirmed | [ICRA]BBB+ | — | ICRA | ₹ 170.75 Cr. | |
| 12 Mar 2026 | Rating action | Crisil BBB+ | — | CRISIL | ₹ 183.71 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 12 Aug 2026 | Financial Results | To consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended June 30, 2026. |
| 21 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 3 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 1 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 22 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 85 | 96 | 88 | 91 | 87 | 93 | 101 | 117 | 126 | 145 | 137 |
| Expenses | 66 | 74 | 83 | 82 | 81 | 83 | 89 | 93 | 103 | 106 | 127 | 117 |
| Operating Profit | 13 | 11 | 13 | 6 | 11 | 4 | 4 | 8 | 14 | 20 | 18 | 20 |
| OPM % | 17% | 13% | 13% | 7% | 12% | 4.1% | 4.2% | 8% | 12% | 16% | 12% | 14% |
| Other Income | 4 | 4 | 4 | 6 | 5 | 0 | −1 | 7 | 2 | 5 | 3 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 15 | 13 | 14 | 10 | 13 | 1 | 0 | 10 | 11 | 19 | 15 | 22 |
| Tax % | 24% | 30% | 24% | 22% | 25% | 4% | 44% | 21% | 26% | 24% | 24% | 24% |
| Net Profit | 11 | 9 | 11 | 8 | 10 | 1 | −1 | 8 | 8 | 15 | 11 | 16 |
| EPS in Rs | 17.76 | 14.41 | 17.56 | 12.67 | 16.25 | 1.26 | −0.84 | 12.37 | 12.79 | 23.86 | 18.37 | 26.63 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 18%
- 5 Years
- 14%
- 3 Years
- 21%
- TTM
- 41%
- 10 Years
- 15%
- 5 Years
- −3%
- 3 Years
- 32%
- TTM
- 181%
- 10 Years
- 24%
- 5 Years
- 0%
- 3 Years
- 13%
- TTM
- —
- 10 Years
- 18%
- 5 Years
- 15%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| NGL Fine Chem Ltd | ₹ 2,598.00 | ₹ 1,632 Cr. | 28.4x | 5x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
Management
- Rajesh N. Lawande
- Chief Financial Officer, Whole Time Director
- Rahul Jayant Nachane
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.